STLN Starling Oncology, Inc.: institutional ownership and insider trading
128 funds reported holding $250M of Starling Oncology, Inc. in their latest 13F filings; in Q2 2026 funds net bought $9.22M, with 26 new positions and 20 funds selling out; over the last 12 months insiders bought $2.69M and sold $2.81M on the open market; over its last four quarters it reported revenue of $587M and net income of $60.6B.
STLN revenue and earnings
- Quarter ended Jun 30, 2026: revenue $161M, net income −$9.79M, EPS -0.08
- Quarter ended Mar 31, 2026: revenue $147M, net income −$2.49M, EPS -0.02
- Quarter ended Dec 31, 2025: revenue $142M, net income $60.7B, EPS -0.04
- Quarter ended Sep 30, 2025: revenue $137M, net income −$16.5M, EPS -0.14
Famous investors holding STLN
- Renaissance Technologies (Renaissance Technologies): $7.42M, 0.0% of the portfolio
- Ken Griffin (Citadel Advisors): $9.44M, 0.0% of the portfolio
- Two Sigma (Two Sigma Investments): $3.63M, 0.0% of the portfolio
- Izzy Englander (Millennium Management): $526K, 0.0% of the portfolio
Largest institutional holders of STLN
- BlackRock, Inc. (BLK) — $25.8M
- DEERFIELD MANAGEMENT COMPANY, L.P. — $18.2M
- VANGUARD CAPITAL MANAGEMENT LLC — $17.7M
- VANGUARD GROUP INC — $16.9M
- JOSH ARNOLD INVESTMENT CONSULTANT, LLC — $13.4M
- GEODE CAPITAL MANAGEMENT, LLC — $10.3M
- CITADEL ADVISORS LLC — $9.44M
- GOLDMAN SACHS GROUP INC (GS, GSCE, GS-PA, GS-PC, GS-PD) — $9.42M
- WEXFORD CAPITAL LP — $9.29M
- SUSQUEHANNA INTERNATIONAL GROUP, LLP — $8.74M
Recent STLN insider trades
- Aug 21, 2026: Hively Brad sold 298,853 shares ($1.95M)
- Aug 14, 2026: Chernett Jorey bought 12,000 shares ($78.5K)
- Jul 21, 2026: Chernett Jorey bought 18,000 shares ($94.9K)
- Jul 14, 2026: Podnos Yale sold 23,452 shares ($150K)
5%+ owners
- Chernett Jorey: 10.2% (Schedule 13G/A, filed Mar 16, 2026)
- M33 Growth I LP: 5.5% (Schedule 13D/A, filed Nov 20, 2025)
Who owns the most STLN stock?
The largest institutional holders of Starling Oncology, Inc. in the latest 13F filings are BlackRock, Inc. (BLK) ($25.8M), DEERFIELD MANAGEMENT COMPANY, L.P. ($18.2M), VANGUARD CAPITAL MANAGEMENT LLC ($17.7M).
Are insiders buying or selling STLN?
Over the last 12 months insiders bought $2.69M and sold $2.81M of Starling Oncology, Inc. stock on the open market (SEC Form 4).
Which famous investors own STLN?
Renaissance Technologies, Ken Griffin, Two Sigma, Izzy Englander.
What was STLN's revenue last quarter?
Starling Oncology, Inc. reported revenue of $161M for the quarter ended June 30, 2026, with net income of −$9.79M.